Novo Nordisk announced that its leading diabetes medication, Ozempic® (semaglutide), has received a positive recommendation in the EU for an updated label to include peripheral arterial disease.
News
Amgen presented Phase 2 data showing that its investigational obesity therapy, maritide, administered monthly, led to significant weight loss in adults with obesity or overweight. The treatment was generally well tolerated, supporting further clinical development.
Novo Nordisk has announced compelling results from its phase 3b STEP UP clinical trial, demonstrating that a higher 7.2 mg dose of its weight-loss medication, Wegovy® (semaglutide), led to a significant average weight loss of 21% in adults with obesity.
AbbVie reported strong results from a Phase 3 head-to-head trial, showing that atogepant (as QULIPTA®/AQUIPTA®) was superior to topiramate on all primary and secondary measures for the preventive treatment of migraine. The results represent a major benchmark in migraine therapy, sitting the CGRP receptor antagonist in place as a potentially […]
Eyestem’s new cell therapy for Dry AMD, showing promising safety and vision improvement in Phase 1 trials. A new hope for treating geographic atrophy.
Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of STELARA® (ustekinumab) to treat pediatric patients two years and older with moderately to severely active Crohn’s disease. This action could mark the availability of a needed new […]
Eli Lilly and Company declared today that Zepbound (tirzepatide), a popular weight-loss drug, will soon be offered in single-dose vials via LillyDirect Self Pay Pharmacy Solutions in all authorized dosages. The goal of this program is to increase the medication’s affordability and accessibility for qualified adults. Regardless of insurance status, […]
Swiss healthcare giant Roche is advancing prasinezumab, a potential first-in-class anti-alpha-synuclein antibody for early Parkinson’s disease, into Phase III trials. This decision follows encouraging data from the Phase IIb PADOVA study and its long-term follow-up, suggesting the drug offers clinical benefits.
In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, JNJ-90014496 (also referred to as JNJ-4496). The treatment has been demonstrated to have a strong success rate for treating patients who have relapsed or are […]
Johnson & Johnson reported encouraging new results from a Phase 1b trial that found its experimental oral medicine, bleximenib, given with the routine treatment regimen of venetoclax plus azacitidine, exhibited strong antileukemic activity in adults with acute myeloid leukemia (AML). The findings, reported at the 2025 European Hematology Association (EHA) […]